Drugs / AS01B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04026009 | Aug 2019 → May 2022 | Clostridium infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03547245 Comparator | Jun 2018 → Jan 2020 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1/2 | NCT03707808 Background | Jan 2018 → Apr 2027 expected | malignant soft tissue neoplasm | University Hospital Brussels | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02044198 Comparator | Mar → Dec 2014 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT01157897 Background | Jul 2010 → Jan 2012 | Plasmodium vivax malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | BioNet-Asia Co., Ltd. | Results Machine Learning in Immunology: From Epitope Prediction to Smarter Vaccine Design bionet-asia.com ↗
What they found was unexpected: AS02A triggered a stronger CD8+ T cell and TFH17 (T follicular helper) response, while AS01B promoted a more immediate antibody surge. |
| 2021-04-21 | ExpreS2ion Biotechnologies | Results Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine expres2ionbio.com ↗
Minassian et al. report that the RH5.1/AS01B vaccine against blood-stage Plasmodium falciparum malaria is safe and immunogenic in the phase I/IIa clinical trial. |
| 2020-10-21 | GlaxoSmithKline | Results GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗
Interim data presented at ID Week show that within one-month post-immunisation, the adjuvanted candidate vaccine has been well tolerated with no safety concerns identified. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-04 | BioNet-Asia Co., Ltd. | Machine Learning in Immunology: From Epitope Prediction to Smarter Vaccine Design bionet-asia.com ↗ |
| 2021-04-21 | ExpreS2ion Biotechnologies | Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine expres2ionbio.com ↗ |
| 2020-10-21 | GlaxoSmithKline | GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗ |
| 2020-03-02 | VBI Vaccines Inc. | VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate, VBI-1901, in Combination with GSK’s AS01B Adjuvant System vbivaccines.com ↗ |
| 2019-09-10 | VBI Vaccines Inc. | VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK’s AS01B Adjuvant System in Recurrent Glioblastoma Patients vbivaccines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS01B | “Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B” NCT01157897 ↗ |
| Action | Activate | “The synthetic saponin-based immune adjuvant AS01B enhances adaptive immunity” PMID 38212127 ↗ Jan 2024 |
| Modality | Other / unclassified | “The synthetic saponin-based immune adjuvant AS01B enhances adaptive immunity through the involvement of myDC.” PMID 38212127 ↗ Jan 2024 |
| Route | Intramuscular | “eOD-GT8 60mer + AS01B/ DPBS sucrose/IM” NCT03547245 ↗ |